Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-2232 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: ALN-2232 | EXPERIMENTAL | Participants will be administered a single dose of ALN-2232 |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo |
| Part B: ALN-2232 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-2232 |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo |
| Part C: ALN-2232 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-2232 |
| Part C: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo |
| Part C: Tirzepatide | OTHER | Participants will be administered multiple doses of tirzepatide once weekly |
| Name | Type | Description |
|---|---|---|
| ALN-2232 | DRUG | ALN-2232 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
| Tirzepatide | DRUG | Tirzepatide will be administered SC |
Inclusion Criteria: All Parts: * Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2 * Has a hemoglobin A1c (HbA1c) \<6.5% Exclusion Criteria: All Parts: * Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise partici...
Top 20 of 33 competitors